Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445248 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
A Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT02445248 is a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 115 participants, below the 251-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02445248, a Phase 2 study of Diffuse Large B Cell Lymphoma (DLBCL), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
Conditions Studied
Interventions
- DRUG Lymphodepleting chemotherapy
- BIOLOGICAL Tisagenlecleucel
Study Locations (20)
Other
- Novartis Investigative Site - Camperdown
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Pierre-Bénite
- Novartis Investigative Site - Würzburg
California
- UCSF Medical Center . - San Francisco
Georgia
- Emory University School of Medicine/Winship Cancer Institute SC CTL019 - Atlanta
Illinois
- University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J - Chicago
Kansas
- University of Kansas Cancer Center SC - CTL019C2201 - Westwood
Maryland
- Sidney Kimmel Comprehensive Cancer Center SC-2 - Baltimore
Michigan
- Uni of Michigan Health System SC CTL019 - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2015-07-29 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02445248
The ClinicalTrials.gov registry entry for NCT02445248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 251-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (54% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 2 interventions - of which Lymphodepleting chemotherapy is the first listed.
NCT02445248 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02445248 about?
NCT02445248 is a clinical study titled "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients". This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
What is the current status of trial NCT02445248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2015-07-29. Estimated completion is 2022-12-22.
What conditions does trial NCT02445248 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT02445248?
The interventions under investigation include: Lymphodepleting chemotherapy (DRUG), Tisagenlecleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02445248?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02445248 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma (DLBCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
RECRUITING · Phase 2
-
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.